Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 995 across all filing types
Latest filing 2019-04-28 Interim / Quarterly Rep…
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Appendix 4C - March 2019 Quarter 7 pages 528.4KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Cashflow Statement: March 2019 Quarter (Q1)' and includes detailed financial data such as cash flows from operating, investing, and financing activities for the quarter ended March 2019. It references compliance with Listing Rule 4.7B and includes an Appendix 4C, which is a standard quarterly report format for entities listed on the Australian Securities Exchange (ASX). The document contains actual financial statements and substantive financial data for a period shorter than a full fiscal year (a quarter). It is not merely an announcement or a certification but a comprehensive quarterly financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2019
2019-04-28 English
Fractionated Prostate Cancer Therapy Published 3 pages 90.8KB
Regulatory Filings Classification · 95% confidence The document is a press release dated April 26, 2019, announcing the publication of clinical data related to fractionated prostate cancer therapy by Telix Pharmaceuticals. It summarizes clinical trial results and highlights treatment benefits, referencing a peer-reviewed journal publication. The document is promotional and informative about clinical data and does not contain financial statements, regulatory filings, or detailed financial performance data. It is not an earnings release, annual report, or any regulatory filing. It is a corporate announcement about clinical data publication relevant to investors. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and corporate update that does not fit other specific categories.
2019-04-25 English
AGM Notice of Meeting and Proxy Form 36 pages 449.2KB
AGM Information Classification · 95% confidence The document is titled 'Notice of Annual General Meeting Explanatory Memorandum' for Telix Pharmaceuticals Limited, dated for a meeting on 22 May 2019. It includes details about the AGM such as the date, time, place, business to be conducted, resolutions to be voted on, voting instructions, and explanatory notes. The content is typical of materials provided to shareholders ahead of an AGM to inform them about the meeting agenda and resolutions. It does not contain financial statements or detailed financial performance data itself, but rather the notice and explanatory memorandum for the AGM. This matches the definition of 'AGM Information' (AGM-R), which includes presentations and materials shared during the Annual General Meeting. The document length is substantial (15,000 characters), indicating it is the full notice and explanatory memorandum, not just a brief announcement. Therefore, the correct classification is AGM-R with high confidence.
2019-04-17 English
Non-Deal Roadshow Presentation March-April 2019 24 pages 3.9MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from Telix Pharmaceuticals Limited, dated March/April 2019, describing the company's business, clinical pipeline, financial snapshot, and upcoming milestones. It includes extensive information on clinical trials, product development stages, market opportunities, and regulatory filing preparations such as NDA filing preparation. The document is structured as a presentation with multiple slides, images, and detailed descriptions of products and trials. It is not a formal regulatory filing, audit report, earnings release, or annual/interim report. It is clearly intended for investors or stakeholders to provide a comprehensive overview of the company's strategy, pipeline, and financial position. This matches the definition of an Investor Presentation (IP). The document length (15,000 characters) and content confirm it is a full presentation rather than a brief announcement or certification. Therefore, the appropriate classification is Investor Presentation (IP).
2019-03-25 English
Telix and Cyclotek Manufacture VisAct ImmunoPET Tracer 2 pages 86.0KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the completion of manufacturing of a new PET imaging tracer, VisAct®, by Telix Pharmaceuticals and Cyclotek. It focuses on product development, clinical trial relevance, and manufacturing milestones. There is no indication of financial data, regulatory filings, voting results, or detailed financial reports. The content is primarily an announcement of a corporate development related to product manufacturing and clinical use, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a general regulatory announcement or corporate update that does not fit other specific categories, thus falling under Regulatory Filings (RNS).
2019-03-20 English
cGMP Manufacturing of TLX250 Renal Cancer Therapy Complete 3 pages 86.8KB
Capital/Financing Update Classification · 90% confidence The document is a press release announcing the completion of cGMP manufacturing of TLX250, a renal cancer therapy drug candidate, and the company's plans to commence clinical trials subject to FDA approval. It provides operational and developmental updates rather than financial data, regulatory filings, or detailed financial reports. There is no indication of financial statements, earnings data, or shareholder meeting materials. The content focuses on manufacturing progress and clinical trial plans, which aligns with a Capital/Financing Update or general corporate announcement. However, since it is about manufacturing completion and clinical trial readiness rather than fundraising or capital structure changes, it fits best under Capital/Financing Update (CAP) as it relates to the company's development progress impacting future financing and clinical trial milestones. The document length is about 5795 characters, which is consistent with a detailed announcement rather than a brief notice or report publication announcement. Therefore, the most appropriate classification is CAP with high confidence.
2019-03-19 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.